Interaction between capecitabine and brivudin in a patient with breast cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 1, 2010, Pages 55-58

  Baena Cañada, José M ^a   Martínez, María J ^a   García Olmedo, Obdulia ^a   Jiménez Bárcenas, Reyes ^a   Muriel Cueto, Pedro ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; IMIPENEM; OMEPRAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD CULTURE; BONE MARROW BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; DRUG DOSE REDUCTION; ENTEROPATHY; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FLUID THERAPY; FOOT CARE; HAND FOOT SYNDROME; HERPES ZOSTER; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MOUTH HYGIENE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONYCHOLYSIS; PARENTERAL NUTRITION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THORAX RADIOGRAPHY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TOOTH DISCOLORATION; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS;

AGED; ANEMIA, APLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BREAST NEOPLASMS; BROMODEOXYURIDINE; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG INTERACTIONS; FATAL OUTCOME; FEMALE; FLUOROURACIL; HERPES ZOSTER; HUMANS; ONYCHOLYSIS; PALLIATIVE CARE; PERIPHERAL NERVOUS SYSTEM DISEASES; SALVAGE THERAPY; STOMATITIS; TOOTH DISCOLORATION;

EID: 76849096060     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.185     Document Type: Article

References (16)

1. Watabe, T., Okuda, H. & Ogura, K. Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil [Japanese]. Yakugaku Zasshi 117, 910-921 (1997). (Pubitemid 28007089)
2. Diasio, R. B. Sorivudine and 5-fluorouracil: a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. J. Clin. Pharmacol. 46, 1-4 (1998).
3. Nakayama, H. et al. Intestinal anaerobic bacteria hydrolyze sorivudine, producing the high blood concentration of 5-(E)-5-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7, 5-43 (1997).
4. Nishiyama, T. et al. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracyl in the presence of NADPH. Mol. Pharmacol. 57, 899-905 (2000).
5. Wassilew, S. W., Wutzler, P. & Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res. 59, 49-56 (2003).
6. De Clercq, E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 68, 2301-2315 (2004).
7. Hogeling, M., Howard, J., Kanigsberg, N. & Finkelstein H. Onycholysis associated with capecitabine in patients with breast cancer. J. Cutan. Med. Surg. 12, 93-95 (2008).
8. Rätz Bravo, A. E., Hofer, S., Krähenbühl, S. & Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol. 22, 1-3 (2009).
9. Hooiveld, E. A., van Kuilenburg, A. B., Haanen, J. B. & Westermann A. M. Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency [Dutch]. Ned. Tijdschr. Geneeskd. 148, 626-628 (2004).
10. McLeod, H. L. et al. Nomenclature for human DPYD alleles. Pharmacogenetics 8, 455-459 (1998).
11. Kohn, L. T. et al. (Eds) To Err Is Human: Building a Safer Health System (National Academies Press, Washington DC, 1999).
12. Huertas, M. J., Baena-Cañada, J. M., Martínez, M. J., Arriola, E. & García, M. V. The impact of computerised chemotherapy prescriptions on the prevention of medication errors. Clin. Transl. Oncol. 8, 821-825 (2006).
13. Johnson, J. A. & Bootman, J. L. Drug-related morbidity and mortality: a cost-of-illness model. Arch. Intern. Med. 155, 1949-1956 (1995).
14. Caranasos, G. J., Stewart, R. B. & Cluff, L. E. Drug-induced illness leading to hospitalization. JAMA 228, 713-717 (1974).
15. Budnitz, D. S. et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296, 1858-1866 (2006).
16. McDonnell, P. J. & Jacobs, M. R. Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. 36, 1331-1336 (2002).